Patents by Inventor Urmas Arumae

Urmas Arumae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of screening cell death modulators
    Patent number: 7642047
    Abstract: The invention provides methods and compositions for identifying agents which modulate cell death, indicated e.g. by the expression of caspase-2 and/or caspase-7, in GDNF family growth factor deprived neuronal or nonneuronal cells. The methods for identifying such agents find particular application in drug development.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: January 5, 2010
    Inventors: Urmas Arumäe, Li-Ying Yu, Mart Saarma
  • Method of screening cell death modulators
    Publication number: 20060057721
    Abstract: The invention provides methods and compositions for identifying agents which modulate cell death, indicated e.g. by the expression of caspase-2 and/or caspase-7, in GDNF family growth factor deprived neuronal or nonneuronal cells. The methods for identifying such agents find particular application in drug development.
    Type: Application
    Filed: January 29, 2004
    Publication date: March 16, 2006
    Inventors: Urmas Arumae, Li-Ying Yu, Mart Saarma
  • Ret-independent signaling pathway for GDNF
    Patent number: 6905817
    Abstract: Methods for screening for agonists and antagonists of GPI-anchored independent intracellular signaling resulting in [Ca2+]i elevation, ERK1, ERK2 and CREB phosphorylation, and Src family kinase activation are described, as well as methods for treatment involving administration of agonists/antagonists of such signaling.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: June 14, 2005
    Assignee: Licestia Ltd.
    Inventors: Alexey Vladimirovich Titievsky, Dmitri Poteriaev, Urmas Arumäe, Mart Saarma
  • Glial cell line-derived neurotrophic factor receptors
    Publication number: 20040126819
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Application
    Filed: September 26, 2003
    Publication date: July 1, 2004
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumae, Petro Suvanto
  • Assays using glial cell line-derived neurotrophic factor receptors
    Patent number: 6696259
    Abstract: Receptors for Glial Cell Line-Derived Neurotrophic Factor (GDNF), their cellular expression, isolation, biochemical characterization, and sequences are disclosed. c-RET is disclosed as one receptor for GDNF; additional novel receptors are also disclosed. The preparation of monoclonal antibodies directed against GDNF is also disclosed.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: February 24, 2004
    Assignee: Licentia Ltd.
    Inventors: Carlos F. Ibanez, Miles Trupp, Mart Saarma, Hannu Sariola, Urmas Arumäe, Petro Suvanto
  • Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth
    Patent number: 5882923
    Abstract: The effect of GDNF on kidney morphogenesis is disclosed. Methods for stimulating budding and branching of the ureteric epithelium, for stimulating axonal outgrowth, for maintaining ureteric epithelial cells in culture, for preventing apoptosis of ureteric epithelial cells, and for treating diseases using GDNF are also disclosed.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: March 16, 1999
    Inventors: Hannu Sariola, Kirsi Sainio, Petro Suvanto, Urmas Arumae, Maria Lindahl, Mart Saarma